Suppr超能文献

机器人非体外循环全内镜冠状动脉旁路移植术在当前时代的应用:544 例患者报告。

Robotic off-pump totally endoscopic coronary artery bypass in the current era: report of 544 patients.

机构信息

Department of Cardiothoracic Surgery, University of Chicago Medicine, Chicago, IL, USA.

出版信息

Eur J Cardiothorac Surg. 2022 Jan 24;61(2):439-446. doi: 10.1093/ejcts/ezab378.

Abstract

OBJECTIVES

Robotic off-pump totally endoscopic coronary artery bypass (TECAB) is the least invasive form of surgical coronary revascularization. It has proved to be highly effective and safe. Its benefits are well-established and include fewer complications, shorter hospital stay and quicker return to normal activities. TECAB has undergone 2 decades of technological advancement to include multivessel grafting, a beating-heart approach and successful completion in multiple patient groups in experienced hands. The aim of this report was to examine outcomes of robotic off-pump TECAB at our institution over 7 years.

METHODS

Data from 544 patients undergoing TECAB between July 2013 and August 2020 were retrospectively examined. The C-Port Flex-A distal anastomotic device was used for the majority of grafts (70%). Yearly follow-up was conducted. Angiographic early patency data were reviewed for patients undergoing hybrid revascularization.

RESULTS

The mean age was 66 years, with 1.7% mean STS risk. Fifty-six percentage had multivessel TECAB. There was 1 conversion to sternotomy, and 46% extubation in the Operating Room (OR). Mortality was 0.9%. Early graft patency was 97%. At mid-term follow-up at 38 months, cardiac mortality was 2.7% and freedom from major adverse cardiac events was 92.5%.

CONCLUSIONS

We conclude that robotic beating-heart TECAB in the current era is safe and effective with excellent outcomes and comparable early angiographic patency to standard coronary artery bypass grafting surgery when performed frequently by an experienced team. This procedure was completed in our hands both with and without an anastomotic device. Longer-term studies are warranted.

摘要

目的

机器人非体外循环全内镜冠状动脉旁路移植术(TECAB)是最微创的外科冠状动脉血运重建形式。它已被证明是高效且安全的。其优势已得到充分证实,包括并发症更少、住院时间更短、更快恢复正常活动。TECAB 经历了 20 年的技术进步,包括多血管桥接、心脏跳动的方法以及在经验丰富的医生手中成功应用于多种患者群体。本报告的目的是检查我们机构在过去 7 年中进行机器人非体外循环 TECAB 的结果。

方法

回顾性分析了 2013 年 7 月至 2020 年 8 月期间 544 例行 TECAB 的患者数据。大多数桥接(70%)使用 C-Port Flex-A 远端吻合装置。进行了每年的随访。对接受杂交血运重建的患者进行了早期血管造影通畅性数据的回顾。

结果

患者平均年龄为 66 岁,平均 STS 风险为 1.7%。56%的患者接受了多血管 TECAB。有 1 例转为开胸,46%在手术室(OR)拔管。死亡率为 0.9%。早期桥接通畅率为 97%。在 38 个月的中期随访中,心脏死亡率为 2.7%,无重大不良心脏事件发生率为 92.5%。

结论

我们的结论是,在当前时代,机器人心脏跳动 TECAB 是安全有效的,具有良好的结果,并且与经验丰富的团队进行的标准冠状动脉旁路移植术的早期血管造影通畅率相当。在我们的手中,这种手术无论是使用吻合装置还是不使用吻合装置都可以完成。需要进行更长期的研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验